{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-015422","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2023-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.084108+00:00","generated_at":"2026-06-11T00:04:14.519015+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Olema raises $130M equity, secures $50M credit facility from SVB","bullets":["Private placement of 13,211,382 shares at $9.84/share raises ~$130M gross.","$50M Silicon Valley Bank credit facility; $25M available at close, $25M discretionary.","Proceeds to fund palazestrant (OP-1250) development and extend runway into 2027.","Lock-up on shares until Phase 1b/2 data release or Dec 31, 2023.","Investors include Paradigm BioCapital, Lightspeed, Deep Track, BVF, Cormorant, Vivo, Logos, Woodline."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-015422","json":"https://secwatch.observer/filing/0001558370-23-015422.json","markdown":"https://secwatch.observer/filing/0001558370-23-015422.md","text":"https://secwatch.observer/filing/0001558370-23-015422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023015422/0001558370-23-015422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023015422/olma-20230905x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:04:14.519015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f0973b32f95afc07b7b79010b8a823ccfc41ca1","claim":"Olema Pharmaceuticals, Inc. entered into Purchase Agreement with the purchasers named therein (the \"Purchasers\") valued at approximately $130 million (effective 2023-09-05).","evidence_excerpt":"On September 5, 2023, Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), which provides for the private placement of 13,211,381 shares (the “Shares”) of the Company’s common stock (the “Common Stock”) at $9.84 per share (such transaction, the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023015422/0001558370-23-015422-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers named therein (the \"Purchasers\")"},{"label":"Value","value":"approximately $130 million"},{"label":"Effective","value":"2023-09-05"}],"fact_type":"material_agreement"},{"claim_id":"a4051f4f61196c670866bf9b3fed86fcc36c8e0a","claim":"Olema Pharmaceuticals, Inc. entered into Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the \"Bank\") valued at up to $50 million (effective 2023-09-05).","evidence_excerpt":"On September 5, 2023, the Company entered into a Loan and Security Agreement (the “Loan Agreement”), by and between the Company, as borrower, and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the “Bank”). The Loan Agreement provides for a four-year senior secured Loan facility in an aggregate principal amount of up to $50 million (the “Loan Facility”), of which $25 million will be available upon the receipt by the Company of $100 million in gross proceeds from the Private Placement, and up to $25 million of which may be made available upon approval of the Bank in its discretion.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023015422/0001558370-23-015422-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the \"Bank\")"},{"label":"Value","value":"up to $50 million"},{"label":"Effective","value":"2023-09-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}